



## MEDIA RELEASE

### US Patent Office issues Notice of Allowance for US Patent

**Melbourne Australia 12 February 2020:** Invictus BioPharma Ltd, the Company commercialising an innovative new non-invasive and direct drug and vitamin delivery platform which eliminates the use of needles, is pleased to announce that the US Patent Office has issued a Notice of Allowance for a patent for the transmucosal delivery of tocotrienols.

The patent covers transmucosal delivery of tocotrienols for promoting the treatment or prevention of post exercise muscle soreness and delayed onset muscle soreness.

This patent formally entitled 'Transmucosal Delivery of Tocotrienol' will provide commercial rights in the US until 13 November 2033.

A divisional patent application covering other indications relevant to the Company's drug development programs in NADFLD/NASH and pancreatic cancer will be lodged shortly.

Invictus BioPharma Ltd Executive Chairman and Chief Executive Officer Dr Glenn Tong said "The grant of the US patent follows closely from the recent granting of an EU patent and is a positive step forward for our patent protection strategy in the two largest markets for nutraceuticals and pharmaceuticals".

Invictus BioPharma has corresponding patents granted in the EU, Japan, Australia, New Zealand, Singapore and South Africa.

For more information please contact:

Dr Glenn Tong  
Invictus BioPharma Ltd.  
Tel: +61 (0) 412 193 350

---

## About Invictus BioPharma Ltd.

Invictus BioPharma Ltd. is an Australian public unlisted biotechnology company developing and commercialising novel dietary supplements and prescription medicines based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery, exercise endurance, Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic SteatoHepatitis (NASH), pancreatic cancer, hyperlipidaemia, hypertension and diabetes. Invictus BioPharma owns and controls patent and other intellectual property rights for novel approaches to non-invasively delivering tocotrienols directly to the target tissues. The Company has a product development program for evidence-based nutraceuticals and a clinical development program for prescription medicines. For more information see: [www.invictusbiopharma.com](http://www.invictusbiopharma.com)